Premium
Prophylactic treatment of skeletal metastases, tumor‐induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl 2 MBP
Author(s) -
Krempien Burkhard,
Manegold Christian
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930701)72:1<91::aid-cncr2820720118>3.0.co;2-2
Subject(s) - medicine , osteolysis , bisphosphonate , prophylactic treatment , surgery , urology , osteoporosis
Background . The purpose of this study was to investigate the influence of a prophylactic bone protective treatment with the bisphosphonate dichloromethane/diphosphonic acid (Cl 2 MBP) in an experimental model of osteolysis with intraosseous implantation of the Walker carcinosarcoma 256 B. Methods . The biphosphonate was given as a high‐dose, short‐term treatment (30 mg/5 days sc) followed by a treatment‐free interval (1–7 weeks) or as a low‐dose, long‐term prophylactic treatment (2.5 or 5.0 mg/day/3 weeks sc). Osteolysis was measured with a radiographic and histologic grading system. Results . The high‐dose short‐term prophylactic treatment was shown clearly to inhibit tumor osteolysis. The osteoprotective effect decreases with increasing length of the treatment‐free interval. A similar positive result could be achieved following the low‐dose long‐term prophylactic treatment. Dosage could not be shown to influence the inhibition of tumor osteolysis in the long‐term bone protective treatment. A possible direct influence of the treatment on tumor growth could be ruled out. The prophylactic treatment does not inhibit body weight increase. Animals treated prophylactically showed less weight loss than the controls after tumor implantation. Conclusions . These results show that a prophylactic treatment with Cl 2 MBPs protects the skeleton effectively against tumor osteolysis. Cancer 1993; 72:91–8.